VerGo Pharma, a leading Contract Research Organization (CRO), announced the successful completion of an unannounced United States Food and Drug Administration (US FDA) inspection at its state-of-the-art Bioanalytical Facility. The audit concluded with Zero (0) observations, confirming absolute compliance with regulatory standards.
An unannounced inspection represents the gold standard for evaluating an organization’s operational readiness. This flawless outcome validates that VerGo Pharma’s processes, scientific personnel, and data integrity standards consistently align with the most rigorous global expectations.
“Achieving this major milestone underscores our everyday commitment to quality and regulatory excellence,” the company stated, expressing sincere appreciation to its exceptional team for their relentless discipline and passion. VerGo Pharma also extended gratitude to its global clients and partners for their enduring trust and confidence.
Moving forward, this compliance milestone serves as a powerful catalyst for the company to continue raising the bar, delivering robust, highly reliable bioanalytical solutions, and supporting its partners’ advanced product portfolios with the highest standards of quality.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
